Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6661111

CC(C)C[C@H](N)C(=O)NCC(=O)OCCCNc1cccc2c1C(=O)c1ccccc1C2=O.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.42
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 2/20 0.42
BLM P54132 2/20 0.42
KMT2A Q03164 2/20 0.42
EGFR P00533 2/20 0.42
MAPK1 P28482 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 1/20 0.42
RAD52 P43351 1/20 0.42
RECQL P46063 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NSD2 O96028 2/20 0.38
FGB P02675 1/20 0.38
MMP14 P50281 1/20 0.38
MAOA P21397 1/20 0.36
LARS1 Q9P2J5 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6667026 0.84 MEN1 (0.46) POLBMAPTSMN1; SMN2MEN1BLM
Trifluoroacetic Acid SCHEMBL6660175 0.83 MAPT (0.49) POLBMAPTSMN1; SMN2MEN1BLM
Trifluoroacetic Acid SCHEMBL6662414 0.83 MAPT (0.49) POLBMAPTSMN1; SMN2MEN1BLM
Trifluoroacetic Acid SCHEMBL6662835 0.83 MAPT (0.47) POLBMAPTSMN1; SMN2MEN1BLM
Trifluoroacetic Acid SCHEMBL6660897 0.82 MEN1 (0.48) POLBMAPTSMN1; SMN2MEN1BLM
Trifluoroacetic Acid SCHEMBL6665362 0.82 MEN1 (0.50) POLBMAPTSMN1; SMN2MEN1BLM
Trifluoroacetic Acid SCHEMBL6663851 0.82 MAPT (0.47) POLBMAPTSMN1; SMN2MEN1BLM
Trifluoroacetic Acid SCHEMBL6664129 0.82 MAPT (0.47) POLBMAPTSMN1; SMN2MEN1BLM
Trifluoroacetic Acid SCHEMBL6659298 0.82 MAPT (0.47) POLBMAPTSMN1; SMN2MEN1BLM
Trifluoroacetic Acid SCHEMBL6663121 0.82 MAPT (0.47) POLBMAPTSMN1; SMN2MEN1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1087935-B1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INT LTD (GB) 2004-08-18 EP disclosed
US-20030203975-A1 Anti-cancer agents BTG INTERNATIONAL LIMITED (GB) 2003-10-30 US disclosed
US-20030024052-A1 Lubricants for elastic fiber SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2003-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203975-A1 Anti-cancer agents TOP2B, TOP2A, TOP1 POLB 14/4885MAPT 4879/4885SMN1; SMN2 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.